DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20195163

Double malignancies: a clinicopathological and outcomes retrospective analysis from a tertiary cancer referral centre in South India

Manjunath I. Nandennavar, Veerendra Angadi, Shashidhar V. Karpurmath, Roshan Jacob

Abstract


Background: The presence of second synchronous or metachronous primary malignancies in a cancer patient is not a rare phenomenon. Our study is an endeavour to present data on the frequency, types, and outcomes of double primary malignancies in Indian cancer patients.

Methods: This was a retrospective study conducted in 28 cancer patients diagnosed with histologically confirmed double malignancy. Retrospective data of the cancer site, patient’s age at the presentation, gender, type of cancer (synchronous/metachronous), treatment, and outcome were recorded from patients presented with double malignancies from January 2012 to January 2019.

Results: Among 28 patients (18 females; 10 males) with multiple primary malignancies, 10 (35.7%) and 18 patients (64.3%), respectively, had synchronous and metachronous primary malignancies. Overall, breast, gynecological, head, and neck cancer were the most common primary malignancies. Gastrointestinal tract, breast, and lung cancer emerged to be the most common second primary malignancy sites. Squamous cell carcinoma (SCC) and invasive ductal carcinoma (IDC) were the most common histopathological types of double malignancies. The majority of the patients received appropriate treatment for both the malignancies.

Conclusions: Data from the present study clearly suggest that the occurrence of second primary malignancy is not rare in Indian cancer patients. The double malignancies can occur at any stage and for any type of cancer. Hence, we wish to highlight that the clinician should always be aware of the possibility of developing second malignancy either during evaluation or in follow up of a patient with malignancy.


Keywords


Double primary malignancy, Metachronous, Survival, Synchronous, Treatment

Full Text:

PDF

References


Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68:394-424.

Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017 May 1;2(2):e000172.

Coyte A, Morrison DS, McLoone P. Second primary cancer risk-the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study. BMC Cancer. 2014 Dec;14(1):272.

THE SEER PROGRAM. Available at: https://seer.cancer.gov/archive/manuals/2004Revision1/SPM_2004_maindoc.r1.pdf. Accessed on: 28 April 2019.

Mukhopadhyay A, Mohanti BK, Sharma K, Das S, Dash S. The economic burden of cancer. Economic and Political Weekly.2011; 43:112-7.

Aziz TM, Saad RA, Glasser J, Jilaihawi AN, Prakash D. The management of second primary lung cancers. A single centre experience in 15 years. Euro J Cardio-Thoracic Surg. 2002 Mar 1;21(3):527-33.

Hujala K, Sipilä J, Grenman R. Panendoscopy and synchronous second primary tumors in head and neck cancer patients. Euro Archi Oto-Rhino-Laryngol Head Neck. 2005 Jan 1;262(1):17-20.

Di Martino E, Sellhaus B, Hausmann R, Minkenberg R, Lohmann M, et al. Survival in second primary malignancies of patients with head and neck cancer. J Laryngol Otol. 2002;116:831-8.

Dequanter D, Shahla M, Lardinois I, Gilbert O, Hanquet O, Tragas G, et al. Second primary lung malignancy in head and neck cancer patients. Eur Ann Otorhinolaryngol Head Neck Dis. 2011;128:11-3.

Brambilla E, Sgarioni AC, Finger G, Sartori G, Cimarosti MJ. Incidence and epidemiological features of synchronous and metachronous colorectal cancer. J Coloproctol (Rio J). 2013;33:58-61.

Popoola AA, Abiola OO, Buhari T, Ushie AF, Olanipekun HB, Arogundade AK. Multiple primary cancers: Simultaneously occurring prostate cancer and other primary tumors-our experience and literature search. Niger J Clin Pract. 2017;20:278-82.

Adeel M, Siddiqi MI. Metachronous second primary malignancy in head and neck cancer patients: is five years of follow-up sufficient? J Korean Assoc Oral Maxillofac Surg. 2018;44:220-4.

Bagri PK, Singh D, Singhal MK, Singh G, Mathur G, Jakhar SL, et al. Double Primary Malignancies: A Clinical and Pathological Analysis Report from a Regional Cancer Institute in India. Iran J Cancer Prev 2014;7:66-72.

R. Balasankar, B. Nehru. A Retrospective Study on Second Primary Malignancies Incidence in Regional Cancer Institute. J Evolution Med Dent Sci. 2015;4;4066-75.

Bansal S, Gupta M, Nautiyal V, Agrawal C, Pruthi D, Chauhan N, et al. Second Primary Neoplasms: A Clinico-Pathological Analysis from a Sub Himalayan Cancer Centre in India. J Integr Oncol. 2017;6:188.

Chaudhary P, Gupta S, Leekha N, Tandon R, Nandy M, De S. Pattern of occurrence and treatment outcome of second primary malignancies: A single center experience. South Asian J Cancer 2017;6:137-8.

Hulikal N, Ray S, Thomas J, Fernandes DJ. Second Primary Malignant Neoplasms: A Clinicopathological Analysis from a Cancer Centre in India. Asian Pac J Cancer Prev. 2012;13:6087-91.

Naik A, Bhandari V, Saadvik RY, Gupta KL, Kausar M, Batra M, et al. Incidence of second primary malignant neoplasm in Malwa region of central India. J Can Res Ther. 2018;14:999-1004.

Sharma D, Singh G, Kakkar N, Raj S. Second primary malignancy: A retrospective analysis report from a tertiary cancer center of North India. Indian J Cancer. 2017:53;595-9.

Jena A, Patnayak R, Lakshmi AY, Manilal B, Reddy MK. Multiple primary cancers: An enigma. South Asian J Cancer. 2016;5:29-32.